Malignant Hepatobiliary Neoplasm — Trials

Malignant Hepatobiliary Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

5,025 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,159
Recruiting: 665
Ph III recruiting: 61
Growth YoY: +9%
Industry share: 22%
Top sponsor: Sun Yat-sen University
Termination share: 32.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (560)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04566393	Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies	available	—	—	xCuresINDUSTRY	1	Jun 4, 2026	clinicaltrials
NCT06751524	Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval	available	—	—	Agenus Inc.INDUSTRY	0	May 15, 2026	clinicaltrials